Jack Jacobs
BIOTECH
President and Chief Scientific Officer
Zhittya Genesis Medicine, Inc.
Dr. Jack Jacobs has been involved in the healthcare industry for over 25 years and has extensive expertise in supervising drug manufacturing operations and the design and implementation of preclinical animal trials and US FDA-authorized clinical trials. He started a new department of Biological Chemistry at Merck and for 15 years worked with Mr. Montano as CardioVascular BioTherapeutics' chief scientific officer where he oversaw FDA-authorized clinical trials in which FGF-1 was tested in a number of medical indications, including coronary artery disease, diabetic foot ulcers, and peripheral artery disease.
Speaker Schedule
Frontiers of Regenerative Medicine: New Therapies for Heart Disease, Neurodegenerative Diseases, and More
August 16, 2020, 3:45 pm - 4:30 pm
Focus: BIOTECH
Heart Disease, Stroke, Diabetes, Parkinson's, Alzheimer's, Multiple Sclerosis: Can Therapeutic Angiogenesis Treat These Disorders?
August 17, 2020, 11:10 am - 11:55 am
Focus: BIOTECH